← All drugs Report issue

azd2927

Small moleculeexperimental

Clinical trial activity

2 trials · 3 clinical orgs · 0 marketing orgs

Phase 1

1

Phase 2

1

Phase 3

0

Phase 4

0

Earliest trial started Jan 1, 2011 (NCT01264250)

Timeline

2010s

Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Jan 1, 2011
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Kir3.1/Kir3.4INHIBITOR
Kir3.1/Kir3.4 inhibitor
- G protein-activated inward rectifier potassium channel 1 (KCNJ3) ↗
- G protein-activated inward rectifier potassium channel 4 (KCNJ5) ↗
- G protein-activated inward rectifier potassium channel 1
- G protein-activated inward rectifier potassium channel 4
Kir3.1/Kir3.2INHIBITOR
Kir3.1/Kir3.2 inhibitor
- G protein-activated inward rectifier potassium channel 1 (KCNJ3) ↗
- G protein-activated inward rectifier potassium channel 2 (KCNJ6) ↗
- G protein-activated inward rectifier potassium channel 2
- G protein-activated inward rectifier potassium channel 1

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

azd2927
azd2927

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT01396226	Phase 2	Sep 1, 2011	AstraZeneca, Linkoping University
NCT01264250	Phase 1	Jan 1, 2011	AstraZeneca, IQVIA

Showing 2 of 2 trials

Page 1 / 1

Organizations

Research & Development (3)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
AstraZeneca	For profit	2	2	2	2011
IQVIA	For profit	1	0	1	2011
Linkoping University	Academic/Hospital	1	0	1	2011

3 organizations

Page 1 / 1